Company Overview and News
2018-10-05 seekingalpha - 8
Nonetheless, the biotech index returns do not appear to be favorable to the risk that biotech investors assume when compared to the performance of broad-based indexes.
VRTX ECYT VKTX ENL AMRN LGNDZ RGNX ARNA LGNYZ ADAP AMGN NBIX ARWR SRPT ICPT RETA VKTXW NDAQ FATE LGNZZ LGND RARX LGNXZ PFE ENDP
2018-10-04 sec.gov - 2
arna-8k_20181004.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
For almost as long as I have covered MannKind (MNKD) I have always stated that I would rather see this company as a research and development entity than one that is attempting to get into the business of sales and distribution. My opinion on that front became more solidified when it was blatantly apparent that MannKind was really struggling to deliver Afrezza sales numbers that were able to impress the Street or help the bottom line.
MNKD ARNA UTHR
2018-10-02 sec.gov - 20
arna-8k_20181002.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Arena Pharmaceuticals (ARNA) posted positive phase 2 results on its Crohn's disease drug candidate Olorinab. The clinical trial was a randomized, open-label, 8-week study investigating two doses of Olorinab (25 mg and 100 mg). Patients in the trial took the drug three times daily. All patients in the trial were diagnosed with quiescent to mild active Crohn's disease associated with chronic abdominal pain defined as a baseline Average Abdominal Pain Score (AAPS) ≥4.
ARNA JNJ UTHR
2018-09-25 zacks - 1
Arena Pharmaceuticals, Inc. (ARNA - Free Report) announced positive top-line data from a phase IIa study, evaluating its investigational cannabinoid receptor 2 (CB2) olorinab (APD371) for the treatment of gastrointestinal pain associated with Crohn's disease.
ARNA FCN ANIK LGNZZ LGND LGNYZ LGNXZ LGNDZ CBM
CenturyLink shares fell about 4 percent in after-hours trading following news that CFO Sunit Patel has resigned from the telecom company, effective Sept. 28. VP of Finance Neel Dev will act as the interim CFO until a permanent replacement is found. Patel will join T-Mobile US as an executive vice president on October 1.
ARNA TMUSP TMUS
2018-09-24 sec.gov - 1
arna-8k_20180924.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-09-05 zacks - 2
A month has gone by since the last earnings report for Arena Pharmaceuticals (ARNA - Free Report) . Shares have added about 7.4% in that time frame, outperforming the S&P 500.
2018-08-30 investorplace - 2
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. The best stocks to buy now go above and beyond the normal growth prospects. While looking for these kinds of investments, I examined seven of the best stocks to invest in, all with huge upside potential and support from the Street’s top analysts.
CBS ARNA CLDR CBS.A NBIX PLAY CPV CBS.WD SBGI LAUR
2018-07-28 - Asif
Overview Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across therapeutic areas. The company's proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. The company's three most advanced investigational clinical programs are: ralinepag (APD811), which Arena Pharmaceuticals is currently preparing for a Phase 3 program for pulmonary arterial hypertension, or PAH; etrasimod (APD334), which is being studied in Phase 2 trials for immune and inflammatory conditions with an initial focus on ulcerative colitis and hepatic conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn's disease, or CD. In addition, Arena Pharmaceuticals has collaborations with the following pharmaceutical companies: Everest Medicines Limited (...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ARNA / Arena Pharmaceuticals, Inc. on message board site Silicon Investor.
as of ET